Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02600429 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
A Phase 3 study, sponsored by ReGenTree.
- Terminated
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
NCT02600429 is a Phase 3 study that was terminated before completion, run by ReGenTree. The registered enrollment target is 18 participants.
The verdict
NCT02600429, a Phase 3 study, was terminated before completion, sponsored by ReGenTree.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of NK.
Interventions
- DRUG Placebo
- DRUG RGN-259
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-09-17 |
| Est. Completion | 2020-03-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02600429
The ClinicalTrials.gov registry entry for NCT02600429 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ReGenTree, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02600429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02600429 about?
NCT02600429 is a clinical study titled "Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1". The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of NK.
What is the current status of trial NCT02600429?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2015-09-17. Estimated completion is 2020-03-09.
What interventions are being tested in trial NCT02600429?
The interventions under investigation include: Placebo (DRUG), RGN-259 (DRUG).
Who is sponsoring clinical trial NCT02600429?
This trial is sponsored by ReGenTree, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.